Cord blood is the blood present in the umbilical cord and placenta after the delivery of a newborn. Before the birth of the baby, stem cells and immune cells are transferred from the mother to the fetus in order to boost the immune systems of the mother and baby in preparation for labor. Thus, at the time of delivery, the blood in the umbilical cord is a rich source of stem cells and other cells of the immune system. [Read more…]
Cord Blood
Because cord blood present within a newborn’s umbilical is rich with stem cells, it can be collected and stored for future medical use.
Invitrx Therapeutics to Co-Sponsor Baylx, Inc’s US FDA Approved Umbilical Cord Tissue Mesenchymal Stem Cells Product for COVID-19
Irvine, CA., November, 23 2020 — Invitrx Therapeutics has formally signed a joint venture agreement with Baylx, Inc. (Baylx), to co-sponsor Baylx’s FDA approved Investigational New Drug (IND) application for BX-U001, a fresh, non-frozen human umbilical cord tissue mesenchymal stem cells (hUC-MSC) product in patients with COVID-19. [Read more…]
Gamida Cell and Be The Match BioTherapies® Expand Strategic Collaboration
Organizations to work together to manage the supply chain for potential commercialization of omidubicel
Omidubicel (NiCord®) is a stem and progenitor cell based product composed of ex vivo expanded allogeneic umbilical cord blood (UCB) cells.
ReeLabs Approved to Conduct First and Only Stem Cell Trial Against COVID-19 in India
ReeLabs received permission from the Central Licensing Authority to conduct the first and only trial in India using MSCs from placenta and umbilical cord tissue against COVID-19.
There are numerous publications that have documented the role of stem cell against COVID-19. Currently there are 23 stem cell trials in progress in US, UK, Japan, Germany, China, Spain, France and various other developed countries and hitherto published literature is extremely encouraging.
India is now all set to join this elite list. [Read more…]
Cord Blood Registry (CBR®) by Generate Life Sciences Partners with NantKwest to Develop Covid-19 Treatment
CBR to Provide Umbilical Cord-Derived Cellular Material to NantKwest for additional COVID-19 Clinical Trials Utilizing MSC Therapy
Los Angeles, Calif., and El Segundo, Calif., August 10, 2020 – CBR® by Generate Life Sciences, the world’s largest private newborn stem cell bank, and NantKwest (Nasdaq: NK), a clinical-stage, natural killer cell-based immunotherapy company, announced a collaboration to develop a COVID-19 treatment leveraging newborn stem cells. CBR will provide research-donated umbilical cord tissue-derived mesenchymal stem cells (MSCs) to NantKwest for efficient and robust expansion utilizing their proprietary modular, closed bioreactor system from NantKwest affiliate ImmunityBio, Inc. [Read more…]
